Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder.

MLA

Thurman, Andrea R., et al. “Safety of Topical Sildenafil Cream, 3.6% in a Randomized, Placebo-Controlled Trial for the Treatment of Female Sexual Arousal Disorder.” The Journal of Sexual Medicine, vol. 21, no. 9, Sept. 2024, pp. 793–99. EBSCOhost, https://doi.org/10.1093/jsxmed/qdae089.

APA

Thurman, A. R., Johnson, I., Cornell, K. A., Hatheway, J., Kim, N. N., Parish, S. J., Dart, C., Friend, D. R., & Goldstein, A. (2024). Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder. The Journal of Sexual Medicine, 21(9), 793–799. https://doi.org/10.1093/jsxmed/qdae089

Chicago

Thurman, Andrea R, Isabella Johnson, Katherine A Cornell, Jessica Hatheway, Noel N Kim, Sharon J Parish, Clint Dart, David R Friend, and Andrew Goldstein. 2024. “Safety of Topical Sildenafil Cream, 3.6% in a Randomized, Placebo-Controlled Trial for the Treatment of Female Sexual Arousal Disorder.” The Journal of Sexual Medicine 21 (9): 793–99. doi:10.1093/jsxmed/qdae089.